TB-500 Legal Status: Pharmacy Rules and the Sports Ban

What FDA says about the substance right now

FDA placed TB-500 in Category 2 on September 29, 2023 ^[13]. Category 2 grouped raw ingredients that carried a serious safety concern. FDA said TB-500 copied a brief stretch of thymosin beta-4. FDA also said key safety facts were missing and the body might react.

FDA's page, as it stood on April 22, 2026, puts the request on its withdrawn list. That means the person or group asking for review pulled the request. FDA hasn't said its old concern went away.

While TB-500 was in that group, FDA said it might act against pharmacies that used it ^[13]. The drug also lacks FDA approval. Those are separate barriers, and both matter.

FDA links TB-500 with thymosin beta-4 because the short chain comes from that protein ^[13]. This is general legal and health information. It isn't legal advice or an offer to provide the substance.

What the July 2026 FDA meeting does not decide

FDA held another public meeting in 2026. The agenda named one form as TB-500 and another as TB-500 with a salt attached. These are two chemical forms of the same short chain, not two proven drugs. The meeting took place July 23–24, 2026 ^[14].

FDA asked the outside panel whether either form may serve as a pharmacy's raw ingredient. The same agenda also covered BPC-157, but that tells you nothing about TB-500 ^[14]. An agenda tells you a discussion happened; it doesn't change the law.

The meeting did not make the substance approved or available ^[14]. FDA staff had advised against adding TB-500 to the list. FDA decides the pharmacy list after hearing from an outside panel ^[15]. As of September 2026, FDA has posted no record of the panel's votes, so you can't treat the meeting as a result.

What the two pharmacy routes allow

Federal law gives drug-making pharmacies two main routes. One route lets a state-licensed pharmacy prepare one patient's drug. A doctor or another licensed prescriber usually must write that patient's valid prescription ^[15].

The other route covers an FDA-registered drug factory. That factory may make larger batches under stricter rules ^[15]. The two routes do not make every raw ingredient lawful.

Only three kinds of raw ingredient qualify. The ingredient may have an official drug rule, appear in an approved medicine, or be on FDA's allowed list ^[15]. Category 1 means FDA may hold off on action while it reviews an ingredient ^[15]. That still doesn't approve the finished drug.

FDA's current page keeps its safety reason for TB-500 but says the request was withdrawn ^[13]. That page is current to April 22, 2026. On it, TB-500 is no longer in Category 2, because its nomination was withdrawn. FDA hasn't explained what the change lets a pharmacy do.

Drug approval is a separate question. TB-500 isn't approved, and it doesn't have Category 1's temporary wait-and-see status ^[13][15]. That leaves no simple legal shortcut for you or a pharmacy.

What a pharmacy must have before making a drug

A made-to-order medicine starts when a licensed doctor or other prescriber sees one patient. The prescriber must decide that the drug fits that person's care. A valid prescription must name that patient ^[15].

Then a state-licensed pharmacy may make the drug for that patient. An FDA-registered drug factory may make larger batches under different rules ^[15]. Neither route makes a barred raw ingredient lawful.

A video or phone visit may be how the patient is seen. It doesn't remove the need for a real link between patient and prescriber, or for a valid prescription ^[15]. It also can't change which substances a pharmacy may use.

For TB-500, FDA now marks the request withdrawn. The old safety reason remains ^[13]. FDA hasn't said whether that change lets a pharmacist use the raw ingredient ^[15]. A prescription alone doesn't settle that question.

This explains the general path. It doesn't name a pharmacy, clinic, video service, or seller. It offers no amount or use directions.

What the sports ban means for TB-500

Yes, tested sport bans TB-500 and thymosin beta-4. The World Anti-Doping Agency puts them in its peptide, growth-factor, and tissue-repair groups. The ban can apply both in and out of a contest ^[16].

Lab tests can find both substances in samples taken from people and horses ^[16]. Racehorse doping cases first drew attention to TB-500. Later work made one test for horses and another for people ^[16].

Why TB-500 is not FDA approved

No treatment using TB-500 has FDA approval ^[13]. FDA once put TB-500, the short part of thymosin beta-4, in Category 2. That group covered substances with serious safety concerns.

FDA warned that the body's defenses might react by some routes. It also said crucial safety facts were absent ^[13]. The warning concerned the raw ingredient a pharmacy would use to make a drug.

Two separate questions matter. Has FDA approved a finished drug? May a pharmacy use the raw ingredient? TB-500 fails the first test, and FDA hasn't answered the second ^[13][15].

Why TB-500 legality isn't a simple yes or no

FDA put TB-500 in Category 2 in September 2023. Its current page says the person or group behind the request withdrew it ^[13]. FDA hasn't said what a pharmacy may now do.

WADA bans the substance in tested sport ^[16]. That rule is clear even though the pharmacy question isn't. This is general FDA information, not legal advice or an offer to supply it ^[13].

Whether a pharmacy may make TB-500

A pharmacy cannot use any raw ingredient it wishes. FDA put TB-500 in Category 2 because it saw a serious safety concern ^[13][15]. The ingredient must also meet the rules for the type of pharmacy making the drug.

FDA's current page now says the request was withdrawn. A licensed prescriber still has to see the patient. Any prescription must be valid ^[15]. But a prescription can't make a disallowed raw material lawful, and FDA hasn't said which side of that line TB-500 now falls on.

How FDA now lists TB-500

On September 29, 2023, FDA put TB-500, the short part of thymosin beta-4, in Category 2 ^[13]. FDA said the substance might pose a serious safety risk. It warned that the body might react, depending on how the substance entered it. Safety facts were also missing.

When a substance was in Category 2, FDA did not promise to hold back action against pharmacies that used it ^[13]. So while it sat there, making the drug could draw agency action. The current page says the request was withdrawn, not approved.

TB-500 was also on the agenda for the July 23–24, 2026 meeting ^[14]. An outside panel took up its use as a pharmacy ingredient. FDA has posted no record of a vote, and a talk is not a decision.